Differential response of cortical-limbic neuropotentiated compulsive mice to dopamine D1 and D2 receptor antagonists

European Journal of Pharmacology

Volumn 371, Issue 2-3, 1999, Pages 103-111

  Campbell, Keith M ^a   McGrath, Michael J ^a   Burton, Frank H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Catalepsy; Compulsive behavior; Glutamate; Mouse; Obsessive Compulsive Disorder (OCD); Tourette's syndrome

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; COMPULSION; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GILLES DE LA TOURETTE SYNDROME; IMMOBILIZATION; MOUSE; NONHUMAN; OBSESSION; PRIORITY JOURNAL; SUPERSENSITIVITY; TRANSGENIC MOUSE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; BEHAVIOR, ANIMAL; CATALEPSY; CEREBRAL CORTEX; CHOLERA TOXIN; COMPULSIVE BEHAVIOR; DOPAMINE ANTAGONISTS; FEMALE; LIMBIC SYSTEM; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOTOR ACTIVITY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SULPIRIDE; TIME FACTORS;

EID: 0032936625     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00184-3     Document Type: Article

References (47)

1. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 12:1990;266-271.
2. Barbas H. Organization of cortical afferent input to orbitofrontal areas in the rhesus monkey. Neuroscience. 56(4):1993;841-864.
3. Bergson C., Mrzlijak L., Smiley J.F., Pappy M., Levenson R., Goldman-Rakic P.S. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptor in primate brain. J. Neurosci. 15:1995;7821-7836.
4. Bernstein I.C., Callahan W.A., Jaranson J.M. Lobotomy in private practice. Arch. Gen. Psychiatry. 32(8):1975;1041-1047.
5. Breiter H.C., Rauch S.L., Kwong K.K., Baker J.R., Weisskoff R.M., Kennedy D.N., Kendrick A.D., Davis T.L., Jiang A., Cohen M.S., Stern C.E., Belliveau J.W., Baer L., O'Sullivan R.L., Savage C.R., Jenike M.A., Rosen B.R. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch. Gen. Psychiatry. 53(7):1996;595-606.
6. Burton F.H., Hasel K., Bloom F.E., Sutcliffe J.G. Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature. 350:1991;74-77.
7. Burton F.H., Forss-Petter S., Battenberg E., Bloom F.E., Sutcliffe J.G. Lethal psychomotor abnormalities in mice caused by a neural cholera toxin transgene. Transgenics. 2:1998;249-257.
8. Campbell K.M., Rohland R.M., McGrath M.J., Satoskar S.D., Burton F.H. Detecting complex repetitive or stereotypic behaviors by graphing behavior as a multifrequency waveform. Physiol. Behav. 64(1):1998;83-91.
9. Campbell, K.M., de Lecea, L., Severynse, D.M., Caron, M.G., McGrath, M.J., Sparber, S.B., Sun, L.-Y., Burton, F.H., 1999. OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J. Neurosci., in press.
10. Carlsson A. Neurocircuitries and neurotransmitter interactions in schizophrenia. Intl. Clin. Psychopharmacol. 10:1995;21-28. Suppl. 3.
11. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13(7):1990;272-277.
12. Cenci M.A., Bj̈orklund A. Transection of corticostriatal afferents reduces amphetamine- and apomorphine-induced striatal fos expression and turning behavior in 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci. 5:1993;1062-1070.
13. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent on the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. USA. 90:1993;9576-9580.
14. Divac I., Fonnum F., Storm-Mathisen J. High affinity uptake of glutamate in terminals of corticostriatal axons. Nature. 266:1977;377-378.
15. Erenberg G. Treatment of Tourtette syndrome with neuroleptic drugs. Adv. Neurol. 58:1992;241-243.
16. Fog R. Neuroleptic action of clozapine injected into various brain areas in rats. Intl. Pharmacopsychiatry. 10(2):1975;89-93.
17. Fonnum F., Storm-Mathisen J., Divac I. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience. 6(5):1981;863-873.
18. Fray P.J., Sahakian B.J., Robbins T.W., Koob G.F., Iversen S.D. An observational method for quantifying the behavioral effects of dopamine agonists: contrasting effects of D-amphetamine and apomorphine. Psychopharmacology. 69:1980;253-259.
19. Fung Y.K., Uretsky N.J. The effect of dopamine uptake blocking agents on the amphetamine-induced circling behavior in mice with unilateral nigro-striatal lesions. J. Pharmacol. Exp. Ther. 214(3):1980;651-656.
20. Gaspar P., Bloch B., LeMoine C. D1 and D2 receptor gene expression in the rat frontal cortex: cellular localization in different classes of efferent neurons. Eur. J. Neurosci. 7(5):1995;1050-1063.
21. Gerfen C.R., Wilson J.W. The basal ganglia. Hndbk. Chem. Neuroanat. 12:1996;371-468.
22. Gold L.H., Geyer M.A., Koob G.F. Neurochemical mechanisms involved in behavioral effects of amphetamines and related designer drugs. NIDA Re. Monogr. 94:1989;101-126.
23. Grobin A.C., Deutch A.Y. Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat. J. Comp. Neurol. 323(3):1998;341-358.
24. Hess E.J., Norman A.B., Creese I. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors. J. Neurosci. 8(7):1988;2361-2370.
25. Horwitz B., Swedo S.E., Grady C.L., Pietrini P., Schapiro M.B., Rapoport J.L., Rapoport S.I. Cerebral metabolic pattern in obsessive-compulsive disorder: altered intercorrelations between regional rates of glucose utilization. Psychiatry Res. 40(4):1991;221-237.
26. Huang Q., Zhou D., Chase K., Gusella J.F., Aronia N., DiFiglia M. Immunocytochemical localization of the D1 dopamine receptor in rat brain reveals its axonal transport, pre- and postsynaptic localization, and prevalence in the basal ganglia, limbic system and thalamic reticular nucleus. Proc. Natl. Acad. Sci. USA. 89:1992;11988-11992.
27. Imperato A., Obinu M.C., Carta G., Mascia M.S., Casu M.A., Dazzi L., Gessa G.L. Neuroleptics cause stimulation of dopamine D1 receptors and their desensitization after chronic treatment. Eur. J. Pharmacol. 264:1994;55-60.
28. Kaneko T., Caria M.A., Asanuma H. Information processing within the motor cortex: II. Intracortical connections between neurons receiving somatosensory cortical input and motor output neurons of the cortex. J. Comp. Neurol. 345(2):1994;172-184.
29. Karler R., Calder L.D., Thai L.H., Bedingfield J.B. A dopaminergic-glutamatergic basis for the action of amphetamine and cocaine. Brain Res. 568(1-2):1994;8-14.
30. Koshikawa N., Aoki S., Tomiyama K., Kobayshi M., Iwata K., Sumino R., Stephenson J.D. Effects of intrastriatal injections of selective D-1 and D-2 agonists and antagonists on jaw movements of rats. Eur. J. Pharmacol. 163(2-3):1989;227-236.
31. Kurlan R., Kersun J., Ballantine H.T., Caine E.D. Neurosurgical treatment of severe obsessive-compulsive disorder associated with Tourette's syndrome. Mov. Disord. 5(2):1990;152-155.
32. McDonald A.J. Organization of amygdaloid projections to the mediodosral thalamus and prefrontal cortex: a fluorescent retrograde transport study in the rat. J. Comp. Neurol. 261(1):1987;46-58.
33. McDonald A.J., Augustine J.R. Localization of GABA-like immunoreactivity in the monkey amygdala. Neuroscience. 52(2):1993;281-294.
34. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabatropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
35. Morecraft R.J., Geula C., Mesulam M.M. Cytoarchitecture and neural afferents of orbitofrontal cortex in the brain of the monkey. J. Comp. Neurol. 323(3):1992;341-358.
36. Rapoport J.L., Swedo S.E., Leonard H.L. Childhood obsessive compulsive disorder. J. Clin. Psychiatry. 53:1992;11-16. Suppl.
37. Reubi J.C., Cuenod M. Glutamate release in vitro from corticostriatal terminals. Brain Res. 176(1):1979;185-188.
38. Rosen, J.B., Davis, M., 1988. Enhancement of acoustic startle by electrical stimulation of the amygdala, Behav. Neurosci., 102, 195-202, 324.
39. Rowlett J.K., Pedigo N.W. Jr., Bardo M.T. Catalepsy produced by striatal microinjections of the D1 dopamine receptor antagonist SCH 23390 in neonatal rats. Pharmacol. Biochem. Behav. 40:1991;829-834.
40. Scatton B. Differential regional development of tolerance to increase in dopamine turnover upon related neuroleptic administration. Eur. J. Neurosci. 46:1977;363-369.
41. Schmidt W.J., Kretschmer B.D. Behavioral pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev. 21(4):1997;381-392.
42. 2 dopamine receptors in the amygdaloid nuclear complex of the rat brain. Synapse. 11(2):1992;146-154.
43. Ushijima I., Mizuki Y., Yamada M. Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment. Pharmacol. Biochem. Behav. 50(2):1995;259-264.
44. Wolf S.S., Jones Q.W., Knable M.B., Gorey J.G., Lee K.S., Hyde T.M., Coppola R., Weinberger D.R. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 273:1996;1225-1227.
45. Yamamoto T., Samejima A., Oka H. The mode of synaptic activation of pyramidal neurons in the cat primary somatosensory cortex: an intracellular HRP study. Exp. Brain Res. 80(1):1990;12-22.
46. Zarrindast M.R., Haibibi-Moini S. Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice. Gen. Pharmacol. 22(6):1991;1023-1026.
47. Zeiger M.A., Motoyasu S., Gusev Y., Westra W.H., Takiyama Y., Dooley W.C., Kohn L.D., Levine M.A. Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology. 138:1997;3133-3140.